Bond & Devick Financial Network Inc. Reduces Stock Holdings in Stryker Co. (NYSE:SYK)

Bond & Devick Financial Network Inc. decreased its holdings in Stryker Co. (NYSE:SYK) by 15.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,492 shares of the medical technology company’s stock after selling 280 shares during the quarter. Bond & Devick Financial Network Inc.’s holdings in Stryker were worth $555,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in SYK. Capital & Planning LLC lifted its position in Stryker by 3.6% during the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock valued at $304,000 after buying an additional 29 shares during the period. Brighton Jones LLC lifted its position in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the period. Strategic Blueprint LLC lifted its position in Stryker by 2.7% during the fourth quarter. Strategic Blueprint LLC now owns 1,465 shares of the medical technology company’s stock valued at $527,000 after buying an additional 39 shares during the period. Crews Bank & Trust purchased a new position in Stryker during the fourth quarter valued at $39,000. Finally, Caprock Group LLC lifted its position in Stryker by 4.0% during the fourth quarter. Caprock Group LLC now owns 8,953 shares of the medical technology company’s stock valued at $3,231,000 after buying an additional 342 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a report on Thursday, March 6th. Truist Financial raised their price target on Stryker from $390.00 to $400.00 and gave the company a “hold” rating in a report on Monday, May 5th. Evercore ISI reduced their price target on Stryker from $400.00 to $390.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. Needham & Company LLC restated a “buy” rating and set a $442.00 price target on shares of Stryker in a report on Friday, March 21st. Finally, Barclays raised their price target on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $427.30.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares of the company’s stock, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.20% of the stock is owned by insiders.

Stryker Trading Up 0.1%

Shares of NYSE:SYK opened at $382.86 on Friday. The stock has a 50 day moving average of $368.77 and a 200 day moving average of $376.14. The company has a market cap of $146.13 billion, a PE ratio of 49.34, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.73 by $0.11. The company had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm’s revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.50 EPS. As a group, equities research analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker’s dividend payout ratio is presently 45.41%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.